An inhibitory role of the phosphatidylinositol 3-kinase-signaling pathway in vascular endothelial growth factor-induced tissue factor expression
- PMID: 11445586
- DOI: 10.1074/jbc.M105474200
An inhibitory role of the phosphatidylinositol 3-kinase-signaling pathway in vascular endothelial growth factor-induced tissue factor expression
Abstract
Vascular endothelial growth factor (VEGF) is not only essential for vasculogenesis and angiogenesis but is also capable of inducing tissue factor, the prime initiator of coagulation, in endothelial cells. In this study we have analyzed the VEGF-elicited pathways involved in the induction of tissue factor in human umbilical cord vein endothelial cells. Using specific low molecular weight inhibitors we could demonstrate a crucial role of the p38 and Erk-1/2 mitogen-activated protein (MAP) kinases. In contrast, treatment with wortmannin or LY294002, inhibitors of phosphatidylinositol 3 (PI3)-kinase, resulted in a strong enhancement of the VEGF-induced tissue factor production, indicating a negative regulatory role of the PI3-kinase on tissue factor-inducing pathways. Accordingly, transduction with constitutively active Akt led to a reduction of VEGF-induced tissue factor production. Western blot analyses using antibodies specific for phosphorylated p38 showed an enhanced activation of this MAP kinase in human umbilical cord vein endothelial cells when stimulated with VEGF in the presence of wortmannin in comparison to either agent alone. Thus, the negative regulation of the PI3-kinase pathway on endothelial tissue factor activity can be explained at least in part by a suppression of this MAP kinase-signaling pathway. This is the first demonstration of a reciprocal relationship between procoagulant activity and the PI3-kinase-Akt signaling pathway, and it reveals a novel mechanism by which tissue factor expression can be controlled in endothelial cells.
Similar articles
-
Negative regulatory role of PI3-kinase in TNF-induced tumor necrosis.Int J Cancer. 2003 Oct 20;107(1):30-7. doi: 10.1002/ijc.11345. Int J Cancer. 2003. PMID: 12925953
-
Akt down-regulation of p38 signaling provides a novel mechanism of vascular endothelial growth factor-mediated cytoprotection in endothelial cells.J Biol Chem. 2001 Aug 10;276(32):30359-65. doi: 10.1074/jbc.M009698200. Epub 2001 May 31. J Biol Chem. 2001. PMID: 11387313
-
Vascular endothelial growth factor induces protein kinase C (PKC)-dependent Akt/PKB activation and phosphatidylinositol 3'-kinase-mediates PKC delta phosphorylation: role of PKC in angiogenesis.Cell Biol Int. 2002;26(9):751-9. doi: 10.1016/s1065-6995(02)90926-1. Cell Biol Int. 2002. PMID: 12377207
-
Phosphatidylinositol 3'-kinase and MAPK/ERK kinase 1/2 differentially regulate expression of vascular endothelial growth factor in human malignant astrocytoma cells.Neuro Oncol. 2002 Oct;4(4):242-52. doi: 10.1093/neuonc/4.4.242. Neuro Oncol. 2002. PMID: 12356354 Free PMC article.
-
Role of crosstalk between phosphatidylinositol 3-kinase and extracellular signal-regulated kinase/mitogen-activated protein kinase pathways in artery-vein specification.Circ Res. 2008 Sep 12;103(6):573-9. doi: 10.1161/CIRCRESAHA.108.180745. Circ Res. 2008. PMID: 18796644 Free PMC article. Review.
Cited by
-
JCAD promotes arterial thrombosis through PI3K/Akt modulation: a translational study.Eur Heart J. 2023 May 21;44(20):1818-1833. doi: 10.1093/eurheartj/ehac641. Eur Heart J. 2023. PMID: 36469488 Free PMC article.
-
Reduced Angiopoietin Factor 2 Levels Are Correlated with Better Cardiac Function and Prognosis in Valvular Heart Disease.Braz J Cardiovasc Surg. 2023 Feb 10;38(1):104-109. doi: 10.21470/1678-9741-2021-0364. Braz J Cardiovasc Surg. 2023. PMID: 35657310 Free PMC article.
-
Medical and Neurological Management of Brain Tumor Complications.Curr Neurol Neurosci Rep. 2021 Sep 20;21(10):53. doi: 10.1007/s11910-021-01142-x. Curr Neurol Neurosci Rep. 2021. PMID: 34545509 Review.
-
The endothelial tumor suppressor p53 is essential for venous thrombus formation in aged mice.Blood Adv. 2018 Jun 12;2(11):1300-1314. doi: 10.1182/bloodadvances.2017014050. Blood Adv. 2018. PMID: 29891592 Free PMC article.
-
FOXC1 in cancer development and therapy: deciphering its emerging and divergent roles.Ther Adv Med Oncol. 2017 Dec;9(12):797-816. doi: 10.1177/1758834017742576. Epub 2017 Nov 23. Ther Adv Med Oncol. 2017. PMID: 29449899 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Miscellaneous